Douglas Miehm
Stock Analyst at RBC Capital
(2.58)
# 1,209
Out of 5,182 analysts
60
Total ratings
52.17%
Success rate
3.21%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Downgrades: Sector Perform | $7.5 → $3.5 | $2.70 | +29.63% | 5 | Feb 27, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $234 → $235 | $231.27 | +1.61% | 8 | Dec 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $15.82 | +20.10% | 14 | Nov 14, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $15.98 | -6.13% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $5.63 | +77.62% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $1.03 | +385.44% | 1 | Mar 10, 2025 |
MannKind
Feb 27, 2026
Downgrades: Sector Perform
Price Target: $7.5 → $3.5
Current: $2.70
Upside: +29.63%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $234 → $235
Current: $231.27
Upside: +1.61%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $15.82
Upside: +20.10%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $15.98
Upside: -6.13%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $5.63
Upside: +77.62%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $1.03
Upside: +385.44%